Key Highlights

  • 8.04% is the move for Savara Inc. (NASDAQ:SVRA) on November 18, 2026, lifting the traded price to USD 4.84 from a calculated prior close of USD 4.48, a calculated gain of USD 0.36 per share.
  • 22 is the day of November 2026 set as the FDA goal date for molgramostim, after a three-month extension that followed a major amendment to the application under priority review.
  • 130 million is the USD of cash, cash equivalents and short-term investments at September 30, 2026, against a third quarter net loss of USD 43 million, up about 45% year over year.
  • 3.79% is the gap above the prior close at the open, followed by a 4.09% move since the open, on reported Volume of 1.89M shares in the November 18, 2026 session.

What Moved Savara Inc. (NASDAQ:SVRA) in Trading on November 18, 2026 (+USD 0.36, +8.04%)

Savara Inc. (NASDAQ:SVRA) traded at USD 4.84 in the November 18, 2026 session, a move of +8.04%. The calculated prior close, the November 17, 2026 regular-session close, is USD 4.48 (USD 4.84 divided by 1.0804), and the calculated USD move is +USD 0.36. The shares opened 3.79% above the prior close, a calculated open near USD 4.65, and traded 4.09% above the open. Reported volume was 1.89M shares. Shares outstanding and a corroborated market Capitalization were not found, so the move is not set against a market value.

The Rationale: FDA Decision Date Approaching for Savara Inc. (NASDAQ:SVRA)

No company release dated November 18, 2026 was identified in published coverage. The nearest scheduled event is the Prescription Drug User Fee Act goal date of November 22, 2026 for molgramostim in autoimmune pulmonary alveolar proteinosis, after the FDA extended its review by three months following a major amendment. As general context, shares of pre-commercial drugmakers often move in the days before a regulatory decision as investors position for either outcome. The product has also been validated for review in the European Union and the United Kingdom under an accelerated 150-day pathway.

Valuation, Liquidity and Risks for Savara Inc. (NASDAQ:SVRA)

Third quarter 2026 Research and Development expense was USD 25 million, up 21%, and general and administrative expense was USD 19 million, up 93%, largely on commercial team growth and stock-based compensation. Operating expenses were USD 44 million, up 44%, and nine-month operating cash burn was USD 105 million. The Hercules Loan Facility carries minimum cash and net product Revenue covenants with dates extended to April 1, 2027 and September 30, 2027. Contingent financing of USD 150 million, split between RTW Investments and Hercules term loans, requires approval by March 31, 2027. A delay or negative decision is the key risk.

Where Things Stand

Savara Inc. (NASDAQ:SVRA) traded at USD 4.84 on November 18, 2026, up 8.04% from a calculated prior close of USD 4.48, after opening 3.79% higher and gaining 4.09% from the open on volume of 1.89M shares. No same-day catalyst was identified in published coverage. The most relevant dated event is the November 22, 2026 FDA goal date for molgramostim. The latest quarter showed a net loss of USD 43 million, operating expenses of USD 44 million and cash and short-term investments of USD 130 million. Contingent funding of up to USD 150 million depends on approval by March 31, 2027. This is not Investment advice.